NCT01693601View on ClinicalTrials.gov

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 18, 2018

Study Completion Date

May 18, 2018

Conditions
Myelofibrosis
Interventions
DRUG

Panobinostat

PO TIW QOW or PO TIW QW

DRUG

Ruxolitinib

PO BID x 28 days

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

John Mascarenhas

OTHER

NCT01693601 - Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) | Biotech Hunter | Biotech Hunter